Medy-Tox Inc. (KOSDAQ:086900)

South Korea · Delayed Price · Currency is KRW

77,300

-700 (-0.90%)

Aug 12, 2026, 3:30 PM KST

-46.36% (1Y)

Market Cap	508.37B -49.7%
Revenue (ttm)	244.02B +2.5%
Net Income	19.61B -7.4%
EPS	3,271.97 +6.3%
Shares Out	6.52M
PE Ratio	23.84
Forward PE	17.91
Dividend	1,200.00 (1.48%)
Ex-Dividend Date	Sep 29, 2025

Volume	21,439
Open	79,500
Previous Close	78,000
Day's Range	76,300 - 80,100
52-Week Range	66,000 - 144,700
Beta	0.42
Analysts	Hold
Price Target	106,000.00 (+37.13%)
Earnings Date	Aug 13, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 689

Stock Exchange KOSDAQ

Ticker Symbol 086900

Full Company Profile

Financial Performance

In 2025, Medy-Tox's revenue was 247.29 billion, an increase of 8.17% compared to the previous year's 228.62 billion. Earnings were 15.62 billion, a decrease of -2.26%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 086900 stock is "Hold." The 12-month stock price target is ₩106,000, which is an increase of 37.13% from the latest price.

Price Target

₩106,000

(37.13% upside)

Analyst Consensus: Hold

Stock Forecasts